Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G.

Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16.

2.

Core binding factor acute myeloid leukaemia and c-KIT mutations.

Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A.

Oncol Rep. 2013 May;29(5):1867-72. doi: 10.3892/or.2013.2328. Epub 2013 Mar 5.

3.

Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.

Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, Bunjes DW, Zhang MJ.

Biol Blood Marrow Transplant. 2015 Mar;21(3):454-9. doi: 10.1016/j.bbmt.2014.11.007. Epub 2014 Nov 15.

4.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N.

Blood. 2014 Aug 21;124(8):1312-9. doi: 10.1182/blood-2014-01-549212. Epub 2014 Jul 8.

5.

Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.

Qin YZ, Zhu HH, Jiang Q, Jiang H, Zhang LP, Xu LP, Wang Y, Liu YR, Lai YY, Shi HX, Jiang B, Huang XJ.

Leuk Res. 2014 Dec;38(12):1435-40. doi: 10.1016/j.leukres.2014.09.017. Epub 2014 Oct 6.

PMID:
25449688
6.

D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.

Yui S, Kurosawa S, Yamaguchi H, Kanamori H, Ueki T, Uoshima N, Mizuno I, Shono K, Usuki K, Chiba S, Nakamura Y, Yanada M, Kanda J, Tajika K, Gomi S, Fukunaga K, Wakita S, Ryotokuji T, Fukuda T, Inokuchi K.

Ann Hematol. 2017 Oct;96(10):1641-1652. doi: 10.1007/s00277-017-3074-y. Epub 2017 Jul 31.

PMID:
28762080
7.

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M.

Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1.

8.

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL).

Ann Oncol. 2017 Nov 1;28(11):2793-2798. doi: 10.1093/annonc/mdx500.

PMID:
28945881
9.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia.

Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9. doi: 10.1016/j.bbmt.2015.10.023. Epub 2015 Nov 10.

10.

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H, Heil G.

J Clin Oncol. 2004 Sep 15;22(18):3741-50. Epub 2004 Aug 2.

PMID:
15289486
11.

Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.

Park SH, Lee HJ, Kim IS, Kang JE, Lee EY, Kim HJ, Kim YK, Won JH, Bang SM, Kim H, Song MK, Chung JS, Shin HJ.

Ann Lab Med. 2015 May;35(3):288-97. doi: 10.3343/alm.2015.35.3.288. Epub 2015 Apr 1.

12.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ.

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

13.

Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Dombret H; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de l'Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups.

Blood. 2003 Jul 15;102(2):462-9. Epub 2003 Mar 20. Review.

14.

Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.

Chen GL, Liu H, Zhang Y, Thomas J, Ross M, Wang ES, Block AW, Sait S, Deeb G, Wallace P, Wetzler M, Hahn T, McCarthy PL.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1369-74. doi: 10.1016/j.bbmt.2014.05.013. Epub 2014 May 24.

15.

[Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].

Qiao M, Li WY, Sun AN, Chen SN, Liang JY, Ding ZX, Feng YF, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):679-83. Chinese.

PMID:
22339826
16.

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B.

J Clin Oncol. 2006 Aug 20;24(24):3904-11.

PMID:
16921041
17.

Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.

Candoni A, De Marchi F, Zanini F, Zannier ME, Simeone E, Toffoletti E, Chiarvesio A, Cerno M, Filì C, Patriarca F, Fanin R.

Exp Hematol. 2017 May;49:25-33. doi: 10.1016/j.exphem.2017.01.005. Epub 2017 Feb 1.

PMID:
28159598
18.

Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Tavernier E, Le QH, Elhamri M, Thomas X.

Leuk Res. 2003 Mar;27(3):205-14.

PMID:
12537972
19.

Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.

Ustun C, Courville EL, DeFor T, Dolan M, Randall N, Yohe S, Bejanyan N, Warlick E, Brunstein C, Weisdorf DJ, Linden MA.

Biol Blood Marrow Transplant. 2016 Apr;22(4):669-675. doi: 10.1016/j.bbmt.2015.10.024. Epub 2015 Nov 10.

20.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.

PMID:
12928754

Supplemental Content

Support Center